About Orphan Reach
Orphan Reach is a company based in Milton Keynes (United Kingdom) founded in 2012 was acquired by Emmes in May 2021. Orphan Reach offers products and services including Biostatistics Services, Clinical Data Management, Clinical Trial Management, Pharmacovigilance Services, and Endpoint Solutions. Orphan Reach operates in a competitive market with competitors including Zenas BioPharma, AllStripes, Prime Global, Agility Clinical and CTI Clinical Trial, among others.
- Headquarter Milton Keynes, United Kingdom
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name The Emmes Company, Llc
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Orphan Reach
Orphan Reach offers a comprehensive portfolio of products and services, including Biostatistics Services, Clinical Data Management, Clinical Trial Management, Pharmacovigilance Services, and Endpoint Solutions.
Statistical support for clinical trial design and analysis
Management of data in clinical research studies
Oversight of trial execution and regulatory affairs
Monitoring and reporting of adverse events in trials
Tools for assessing trial endpoints and patient outcomes
Funding Insights of Orphan Reach
Detailed funding history for Orphan Reach
Round names, dates, amounts, investors, and valuation history require an active premium plan.
- Round names and dates
- Funding amounts
- Participating investors
- Valuation history
Verified entity values are shown only after access is granted.
Investors in Orphan Reach
Orphan Reach has secured backing from 1 investor. Prominent investors backing the company include Emmes.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Outsourced contract research organization services are provided to clients.
|
Locked | Locked | Locked |
Investor details for Orphan Reach
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Orphan Reach
Investment portfolio details for Orphan Reach
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Orphan Reach
Detailed financials for Orphan Reach
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Orphan Reach Comparisons
Peer comparison for Orphan Reach
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Orphan Reach
Orphan Reach operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Zenas BioPharma, AllStripes, Prime Global, Agility Clinical and CTI Clinical Trial, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Clinical development services for autoimmune and rare diseases are provided.
|
|
| Locked | Locked | Locked |
Provider of information to patients and communities with the medical data for rare diseases
|
|
| Locked | Locked | Locked |
Medical communication solutions are provided for healthcare professionals.
|
|
| Locked | Locked | Locked |
CRO with a special focus on orphan drug development
|
|
| Locked | Locked | Locked |
Provides clinical trials, consulting, and regulatory services in healthcare sectors.
|
|
| Locked | Locked | Locked |
Biotech company focused on developing therapies for rare diseases, with a current focus on Hirschsprung disease
|
Detailed competitors of Orphan Reach
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Orphan Reach
Complete news archive for Orphan Reach
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Orphan Reach
Orphan Reach was founded in 2012.
Orphan Reach is headquartered in Milton Keynes, United Kingdom.
Orphan Reach is a CRO focussed on rare diseases and orphan drugs development. They offer early development services (regulatory strategy planning, orphan drug designation, FDA and EMA Meeting Preparation and Representation etc.,), natural history studies (studies that follow a group of people over time who have or are at risk of developing a specific disease), clinical trial management solutions (project management, biostatistics, regulatory affairs etc.,), patient home support and post marketing surveillance services. They claim to have special focus on patient recruitment and retention for orphan drug trials. They also offer their services for pediatric drugs and rare diseases. They claim to have access to patients with rare diseases in more than 100 countries world-wide.
Orphan Reach's top competitors include Zenas BioPharma, AllStripes and Prime Global.
Orphan Reach offers Biostatistics Services, Clinical Data Management, Clinical Trial Management, Pharmacovigilance Services, and Endpoint Solutions.
Orphan Reach has 1 investor. Key investors include Emmes.